Immune to Cancer: The CRI Blog
-
AACR 2022 Preview: Decoding Cancer Complexity, Integrating Science, and Transforming Patient Outcomes
During AACR’s upcoming 2022 annual meeting, CRI scientists will share the latest advances in cancer immunotherapy.
-
FDA Immunotherapy Approvals in 2022
As drug development in cancer immunotherapy has accelerated, the U.S. Food and Drug Administration has made several…
-
Mining the Mysteries of Myeloid Cells with CRI Lloyd J. Old STAR Malay Haldar
CRI Lloyd J. Old STAR Malay Haldar is exploring the role of dendritic cells and macrophages in…
-
FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination
Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…
-
Neutrophils and Inflammation in Colorectal Cancer with CRI Lloyd J. Old STAR Ivan Zanoni
CRI Lloyd J. Old STAR Ivan Zanoni is exploring the multifaceted roles of neutrophils in colorectal cancer.
-
Kidney Cancer Awareness Month: 2022 Immunotherapy Research Updates
This March for Kidney Cancer Awareness Month, discover the patient perspectives, clinical trials, and progress for a…
-
Novel CAR Immunotherapies for Pancreatic Cancer with Dr. Ryan Alexander
CRI Fellow Ryan Alexander is developing new cellular immunotherapies for pancreatic cancer.
-
Colorectal Cancer Awareness Month: 2022 Immunotherapy Research Updates
This March for Colorectal Cancer Awareness Month, discover the latest clinical trials, research insights, and progress for…
-
Multiple Myeloma Awareness Month: 2022 Immunotherapy Research Updates
This March for Multiple Myeloma Awareness Month, discover the latest treatments, research insights, and progress for a…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.